ClinicalTrials.Veeva

Menu

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma (CSSG-03)

P

Peking University

Status and phase

Unknown
Phase 2

Conditions

Advanced Cancer
Quality of Life
Effect of Drugs
Chordoma

Treatments

Drug: Anlotinib Hydrochloride

Study type

Interventional

Funder types

Other

Identifiers

NCT04042597
PKUPH-sarcoma 05

Details and patient eligibility

About

For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high affinity, which also showed broad antitumor activity against EGFR and so on. Thus this multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the efficacy and safety of anlotinib versus imatinib on advanced chordoma.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years and older;
  • histologically proven metastatic or locally advanced chordoma, reviewed by the Pathology Committee of Peking University People's Hospital;
  • not amenable to curative-intent surgery;
  • measurable with computed tomography scan or magnetic resonance imaging, per RECIST, version 1.1.

Exclusion criteria

  • Eastern Cooperative Oncology Group (ECOG)30 performance status more than 2 ;
  • life expectancy less than 12 weeks;
  • with severe or uncontrolled medical disorders (≥grade 2 of Common Terminology Criteria for Adverse Events version 4.03 [CTCAE version 4.03]) that could jeopardise the outcomes of the study, for example, cardiac clinical symptom or disease with LVEF (left ventricular ejection fraction) <50%, hypertension that could not be well controlled through antihypertensive drugs and so on;
  • weight loss of 20% or more before illness;
  • brain or leptomeningeal metastasis;
  • surgical procedure or radiotherapy within 4 weeks of enrollment;
  • active gastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation;
  • proteinuria or hematuria;
  • denutrition with albuminemia less than 25 g/L;
  • pregnant or breastfeeding status;
  • other malignancy, positive HBV/HCV/HIV serology;
  • known allergy to the experimental agents;
  • had ever used anti-angiogenesis TKIs.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Arm A: anlotinib arm
Experimental group
Description:
anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
Treatment:
Drug: Anlotinib Hydrochloride
Arm B: imatinib arm
Active Comparator group
Description:
Imatinib was given at dose of 400 mg twice daily continuously
Treatment:
Drug: Anlotinib Hydrochloride

Trial contacts and locations

1

Loading...

Central trial contact

Jie Xu, M.D.; Lu Xie, M.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems